What Imaging Is Best for a Palpable Breast Mass in a Male Under 25?

A 19-year-old male presents to your clinic for evaluation of a palpable lump in his left breast he first noticed a month ago. He denies pain, nipple discharge, or skin changes. On physical examination, you feel a 2 cm, mobile, rubbery, subareolar mass, but the findings are not definitive for classic gynecomastia. You are now faced with a decision: what is the most appropriate initial imaging study to order? This is a common clinical question, and navigating the options requires a clear understanding of the differential diagnosis and the relative strengths of each imaging modality in this specific patient population. For a male younger than 25 with an indeterminate palpable breast mass, the American College of Radiology (ACR) Appropriateness Criteria rates breast ultrasound as Usually Appropriate as the initial imaging study.

Who Fits This Clinical Scenario for a Male Breast Mass?

This clinical workflow is specifically for male patients younger than 25 years of age who present with a palpable breast mass that is considered “indeterminate” on physical examination. An indeterminate finding is one that does not have the classic features of gynecomastia (e.g., diffuse, flame-shaped, bilateral, or tender subareolar tissue) and is not overtly suspicious for malignancy (e.g., hard, fixed, associated with skin retraction or axillary adenopathy).

This guidance does not apply to several similar, but distinct, clinical situations:

• Classic Gynecomastia: If the physical exam is clearly consistent with gynecomastia or pseudogynecomastia (fat deposition without glandular proliferation), imaging is often not required. That presentation follows a different diagnostic pathway.
• Patients 25 or Older: The imaging algorithm changes for men 25 and older. In that age group, the pre-test probability of malignancy, though still low, is higher, and mammography plays a more prominent initial role.
• Suspicion of Malignancy: If the physical exam reveals features highly suspicious for breast cancer—such as a hard, non-mobile mass, skin dimpling, nipple retraction, or palpable axillary lymph nodes—the workup is more urgent and follows a different ACR variant.

Correctly identifying that your patient fits this specific scenario—young, male, with an equivocal palpable finding—is the crucial first step to ordering the right test and avoiding unnecessary procedures or radiation exposure.

What Diagnoses Are You Working Up in a Young Male with a Breast Mass?

When ordering imaging for an indeterminate breast mass in a male under 25, you are primarily working to differentiate benign from malignant causes, though benign findings are overwhelmingly more common. The differential diagnosis guides the choice of imaging.

Gynecomastia: This is, by a significant margin, the most common cause of a palpable breast mass in this age group. It represents a benign proliferation of glandular breast tissue. While often diffuse, it can present as a focal, palpable nodule, making it clinically indeterminate from a true mass. Pubertal gynecomastia is a normal physiologic finding that affects a large percentage of adolescent males and typically resolves spontaneously.

Benign Masses: Other non-cancerous lesions can occur, though they are less common than gynecomastia. These include lipomas (benign fatty tumors), epidermal inclusion cysts (skin cysts), and duct ectasia (dilation of breast ducts). These can all present as palpable lumps and are important to distinguish from more concerning pathologies.

Male Breast Cancer: This is the most consequential diagnosis on the differential, but it is exceedingly rare in men under 25. While it must be considered to ensure it is not missed, the clinical workflow is designed with its very low prevalence in mind. The goal is to rule it out efficiently without subjecting the vast majority of patients with benign conditions to overly aggressive testing.

Inflammatory Conditions or Abscess: Though less common without corresponding signs of infection like erythema, warmth, or significant tenderness, a localized infection or abscess can present as a palpable mass. Ultrasound is highly effective at identifying fluid collections that would suggest this diagnosis.

Why Is Breast Ultrasound the Recommended First Study for This Presentation?

The ACR designates breast ultrasound as Usually Appropriate for this scenario because it directly and effectively addresses the primary clinical questions without the drawbacks of other modalities. The rationale is rooted in its diagnostic capability, safety profile, and efficiency.

Ultrasound excels at differentiating the most common etiologies. It can readily distinguish between the fibrillar, flame-shaped appearance of glandular tissue in gynecomastia and a discrete, circumscribed solid or cystic mass. This is often the only characterization needed to resolve the clinical question. If a true mass is identified, ultrasound can assess its features (e.g., shape, margins, vascularity) to determine if it is benign-appearing or suspicious, guiding further management.

Critically, breast ultrasound involves no ionizing radiation (0 mSv). This is a paramount consideration in a young patient population where cumulative radiation exposure should be minimized. The breast tissue in young men is also typically dense, which can limit the sensitivity of mammography, making ultrasound a more effective initial tool.

Alternative imaging studies are rated lower for specific reasons in this context:

• Mammography or Digital Breast Tomosynthesis: These are rated as May be appropriate. They are not the first-line choice because of the ionizing radiation dose (ACR RRL ☢☢, 0.1-1 mSv) and the often-dense breast tissue in young men, which can produce an indeterminate result. Mammography is typically reserved for cases where ultrasound findings are suspicious or equivocal, serving as a problem-solving tool rather than an initial screening one.
• Breast MRI (with or without contrast): This is rated as Usually not appropriate. While highly sensitive, MRI lacks specificity in this setting and can lead to a high rate of false positives for what is almost always a benign condition. This can trigger unnecessary anxiety and biopsies. Its use is reserved for specific indications, such as post-cancer staging or evaluating implant integrity, not for the initial workup of an indeterminate palpable mass in a young male.

What’s the Next Step After a Breast Ultrasound? Downstream Workflow

The results of the breast ultrasound will dictate the subsequent steps in the patient’s care. The radiologist will typically categorize the findings using the Breast Imaging Reporting and Data System (BI-RADS) score, which provides a clear roadmap for management.

• Findings Consistent with Gynecomastia (BI-RADS 2): If the ultrasound confirms classic features of gynecomastia corresponding to the palpable lump, the workup is complete. The appropriate next step is clinical reassurance and routine follow-up. No further imaging is necessary.
• Simple Cyst or Benign-Appearing Solid Mass (BI-RADS 2): If a simple cyst, lipoma, or other definitively benign lesion is found, this is also considered a negative workup. Management consists of reassurance.
• Probably Benign Finding (BI-RADS 3): If the ultrasound identifies a solid mass that is likely benign (e.g., circumscribed, oval), the standard recommendation is short-term imaging follow-up, typically with another ultrasound in 6 months, to ensure stability.
• Suspicious Abnormality (BI-RADS 4 or 5): If the mass has features suspicious for malignancy (e.g., irregular shape, spiculated margins), the definitive next step is an ultrasound-guided core needle biopsy for pathologic diagnosis. This finding should prompt a prompt referral to a breast surgeon.
• Negative or Normal Ultrasound (BI-RADS 1): If the ultrasound shows no abnormality in the area of palpable concern, the finding is likely due to normal prominent tissue. Clinical correlation is key, and if a discrete lump persists on exam, a surgical consultation may still be considered, though further imaging is generally not indicated.

Pitfalls to Avoid (and When to Get Help)

Navigating this clinical scenario is generally straightforward, but a few common pitfalls can lead to diagnostic delay or unnecessary testing.

1. Ordering Mammography First: The most common misstep is ordering mammography as the initial test in this under-25 age group. This leads to unnecessary radiation exposure and may yield an inconclusive result due to dense breast tissue, requiring an ultrasound anyway. Always start with ultrasound.
2. Dismissing a Persistent Palpable Finding: If a patient has a persistent, discrete palpable mass but the ultrasound is reported as negative, do not ignore the physical exam. Ensure the sonographer specifically evaluated the area of concern (sometimes marked with a skin marker) and consider a surgical referral if the clinical suspicion remains.
3. Incomplete Clinical Information: Failing to provide the radiologist with a clear history and the specific location of the palpable mass can compromise the diagnostic accuracy of the ultrasound. Always specify the location (e.g., “palpable lump, left breast, 2 o’clock, 3 cm from nipple”).

If the ultrasound returns with a BI-RADS 4 or 5 category, indicating a suspicious finding, the situation requires escalation. This patient should be referred promptly to a breast specialist or surgeon for consultation and tissue sampling.

Related ACR Topics and Tools

This article covers one specific scenario within the broader ACR guidelines for the symptomatic male breast. For a comprehensive overview of all related scenarios, from classic gynecomastia to workup in older men, please see our parent guide. You can also use the tools below to explore other criteria, protocols, and radiation dose information.

• For breadth across all scenarios in Evaluation of the Symptomatic Male Breast, see our parent guide: Evaluation of the Symptomatic Male Breast: ACR Appropriateness Decoded.
• Imaging Appropriateness Selector — for adjacent scenarios
• Imaging Protocol Library — for technique on the recommended study
• Radiation Dose Calculator — for cumulative dose conversations

Frequently Asked Questions

Is male breast cancer a real concern in someone under 25?

While male breast cancer must be on the differential diagnosis, it is exceptionally rare in this age group. The vast majority of palpable breast masses in men under 25 are benign, most commonly gynecomastia. The diagnostic workflow is designed to confidently exclude malignancy while minimizing unnecessary testing and radiation for the majority of patients.

What if the patient is 26 years old? Does this workflow still apply?

No. The ACR guidelines use age 25 as a key branching point. For a male 25 years of age or older with an indeterminate palpable mass, both mammography and ultrasound are considered appropriate initial imaging studies. The increased (though still low) risk of malignancy in this older age group justifies the use of mammography upfront.

If the ultrasound shows gynecomastia, does the patient need any follow-up?

If the ultrasound findings are classic for gynecomastia and correlate with the palpable area, no further imaging follow-up is needed. Management should focus on clinical reassurance. If the gynecomastia is a new finding, a clinical evaluation for underlying causes (e.g., medications, hormonal imbalances) may be warranted, but the breast imaging workup is complete.

Why isn’t MRI recommended if it’s so sensitive?

Breast MRI is rated ‘Usually not appropriate’ for this scenario because its high sensitivity comes at the cost of low specificity. In a low-prevalence condition like male breast cancer in the under-25 population, this would lead to a high number of false-positive results, prompting unnecessary biopsies and patient anxiety for what is overwhelmingly a benign process. It is the wrong tool for this specific initial evaluation.

Should I order a bilateral or unilateral breast ultrasound?

The order should specify a unilateral ultrasound targeted to the symptomatic breast. The ACR guidelines state that a ‘US breast’ is appropriate, which is typically interpreted as a targeted, unilateral examination of the area of concern. A bilateral exam is generally not necessary unless there are palpable findings in both breasts.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 26, 2026